Aureka Biotechnologies Raises $100M Series B for Biological Foundation Models

Aureka Biotechnologies announced $100M in Series B financing on August 10, 2026. Aureka Biotechnologies closed a $100 million Series B to train biological foundation models and expand its experiment-centered drug-discovery platform.

Round details

The financing includes backing from Granite Asia, HighLight Capital, MPCi. The company did not publish a valuation with the announcement.

Round: Series B
Capital announced: $100M
Total funding reported: ~$200M
Headquarters: Laguna Hills, CA and Shanghai

How the company plans to use the capital

Aureka plans to train its next generation of biological models and expand Lab-in-the-Loop, connecting model output with single-cell screening and experimental validation.

Why this matters for GTM teams

The deal illustrates how capital is moving toward vertically integrated AI companies that combine proprietary models, data generation, and physical experimentation.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Aureka Biotechnologies company announcement.